Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Background: The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with currently no approved molecularly-targeted therapies. The oncogenic signaling pathways driving basal-like tumorigenesis are not fully elucidated. Methods: One hundred sixteen unselected breast tumors were subjected to integrated analysis of phosphoinositide 3-kinase (PI3K) pathway related molecular aberrations by immunohistochemistry, mutation analysis, and gene expression profiling. Incidence and relationships between molecular biomarkers were characterized. Findings for select biomarkers were validated in an independent series. Synergistic cell killing in vitro and in vivo tumor therapy was investigated in breast cancer cell lines and mouse xenograft models, respectively. Results: Sixty-four % of cases had an oncogenic alteration to PIK3CA, PTEN, or INPP4B; when including upstream kinases HER2 and EGFR, 75 % of cases had one or more aberration including 97 % of estrogen receptor (ER)-negative tumors. PTEN-loss was significantly associated to stathmin and EGFR overexpression, positivity for the BLBC markers cytokeratin 5/14, and the BLBC molecular subtype by gene expression profiling, informing a potential therapeutic combination targeting these pathways in BLBC. Combination treatment of BLBC cell lines with the EGFR-inhibitor gefitinib plus the PI3K pathway inhibitor LY294002 was synergistic, and correspondingly, in an in vivo BLBC xenograft mouse model, gefitinib plus PI3K-inhibitor PWT-458 was more effective than either monotherapy and caused tumor regression. Conclusions: Our study emphasizes the importance of PI3K/PTEN pathway activity in ER-negative and basal-like breast cancer and supports the future clinical evaluation of combining EGFR and PI3K pathway inhibitors for the treatment of BLBC.

Detaljer

Författare
  • Qing Bai She
  • Sofia Gruvberger
  • Matthew Maurer
  • Yilun Chen
  • Mervi Jumppanen
  • Tao Su
  • Meaghan Dendy
  • Ying Ka Ingar Lau
  • Lorenzo Memeo
  • Hugo M. Horlings
  • Marc J. van de Vijver
  • Jorma Isola
  • Hanina Hibshoosh
  • Neal Rosen
  • Ramon Parsons
  • Lao H. Saal
Enheter & grupper
Externa organisationer
  • University of Kentucky
  • Columbia University
  • Mediterranean Institute of Oncology
  • Netherlands Cancer Institute
  • University of Tampere
  • Memorial Sloan-Kettering Cancer Center
  • Icahn School of Medicine at Mount Sinai
  • South Ostrobothnia Central Hospital
  • Academic Medical Center
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi

Nyckelord

Originalspråkengelska
Artikelnummer587
TidskriftBMC Cancer
Volym16
Utgivningsnummer1
StatusPublished - 2016 aug 2
PublikationskategoriForskning
Peer review utfördJa